Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$7.41 -0.00%

-$0.00 today

Market cap
$933.77M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 2.87M

Average 2.58M

VSTM EBITDA Margin

EBITDA as a percentage of revenue.

Verastem, Inc.NASDAQ: VSTM

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin at -192.4%

EBITDA Margin was -192.4% in Q1 FY2026. On a trailing-twelve-month basis it was -387.1%, up 1063.3 pp year over year. Over 3 fiscal years it widened by 2084.9 pp.

Context

  • EBITDA Margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -125.1% for the fiscal year ending Dec 2026, up from -671.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-192.4%-8.8 pp QoQ
Last fiscal yearDec 2025
-671.6%+587.1 pp YoY
LTMMar 2026
-387.1%+1063.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—+1010.0 pp—
1 year+587.1 pp+546.5 pp-40.6 pp
3 years+2084.9 pp+625.6 pp-1459.3 pp
5 years+670.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-671.6%
Year-over-year change
+587.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How VSTM compares with its peers on the latest reported figures

  • VSTM's LTM Mar 2026 EBITDA Margin of -387.1% is the 4th highest of the 7 companies compared; the peer median is -371.6%.
  • Its year-over-year change of +1063.3 pp is the 3rd highest of 6, against a peer median of +77.3 pp.
  • Over three fiscal years its change of +2084.9 pp compares with a peer median of +319.4 pp.
VSTM Competitors Peer median
EBITDA Margin for VSTM and competitors
Company Period LTM level YoY 3-year change
NUVBNuvation Bio Inc.LTM Jun 2026-74.8% +1326.6 pp—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-257.0% +77.3 pp+319.4 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-287.9% -44.6 pp+113.4 pp
VSTMVerastem, Inc.LTM Mar 2026-387.1% +1063.3 pp+2084.9 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-455.3% +1345.3 pp—
ANLAdlai Nortye Ltd.LTM Jun 2024-979.5% ——
CRDFCardiff Oncology, Inc.LTM Mar 2026-8329.5% -111.2 pp+2386.2 pp
ORICORIC Pharmaceuticals, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
BBOTBridgeBio Oncology Therapeutics Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding VSTM) -371.6%+77.3 pp+319.4 pp

Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.05M2.6M010M30.91M
Cost of Revenue00005.3M
Gross Profit2.05M2.6M010M25.62M
Gross Margin100.0%100.0%—100.0%82.9%
Research & Development39.35M50.56M61.36M81.33M114.6M
Selling, General & Admin24.12M24.98M30.73M43.62M81.15M
Operating Expenses63.46M75.53M92.08M124.96M195.75M
Depreciation & Amortization72K118K62K26K728K
EBITDA(61.16M)(71.56M)(83.17M)(125.86M)(207.61M)
EBITDA Margin-2978.9%-2756.4%—-1258.6%-671.6%
Operating Income(61.41M)(72.94M)(92.08M)(114.96M)(170.13M)
Operating Margin-2991.2%-2809.6%—-1149.6%-550.3%
Interest Income181K1.22M6.21M4.15M4.07M
Interest Expense9.97M2.14M4.14M4.56M1.14M
Other Income / Expenses(9.79M)(875K)4.72M(15.5M)(39.34M)
Income Before Tax(71.2M)(73.81M)(87.37M)(130.45M)(209.47M)
Pre-Tax Margin-3468.1%-2843.3%—-1304.5%-677.6%
Income Tax Expense000185K0
Net Income(71.2M)(73.81M)(87.37M)(130.64M)(209.47M)
Net Margin-3468.1%-2843.3%—-1306.4%-677.6%
EPS (Basic)(4.92)(4.57)(3.96)(3.66)(3.02)
EPS (Diluted)(4.92)(4.57)(3.96)(3.66)(3.02)
Weighted Avg Shares14.53M16.14M22.05M35.71M69.31M
Weighted Avg Shares (Diluted)14.53M16.14M22.05M35.71M69.31M

Verastem, Inc.

NASDAQ:VSTM

Intrinsic Alpha fair value

Locked

Current Price

$7.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.